Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Number of holders
-
329
-
Total 13F shares, excl. options
-
132,146,550
-
Shares change
-
-3,369,891
-
Total reported value, excl. options
-
$5,510,245,951
-
Value change
-
-$141,977,795
-
Put/Call ratio
-
98.6%
-
Number of buys
-
163
-
Number of sells
-
-170
-
Price
-
$41.69
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q1 2021
390 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q1 2021.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 329 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 132,146,550 shares
.
Largest 10 shareholders include BlackRock Inc. (18,437,478 shares), VANGUARD GROUP INC (13,257,866 shares), Artisan Partners Limited Partnership (10,468,159 shares), Invesco Ltd. (5,521,734 shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (5,337,462 shares), JPMORGAN CHASE & CO (5,119,082 shares), STATE STREET CORP (5,033,216 shares), Bellevue Group AG (3,011,966 shares), SNYDER CAPITAL MANAGEMENT L P (2,920,860 shares), and GOLDMAN SACHS GROUP INC (2,624,709 shares).
This table shows the top 329 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.